Hims Hers Health is trading 4.4% down at $31.30 as investors lock in gains following a strong recent rally and ahead of a pivotal regulatory event.
- The decline is largely attributed to investor caution surrounding an upcoming FDA compounding advisory committee meeting focused on peptides.
- Today's price action appears to be a technical pullback and profit-taking move rather than a reaction to any new negative company-specific announcements or earnings shocks.
- The stock remains under close watch as the market awaits clarity from the regulatory meeting regarding compounding guidelines.